表紙
市場調査レポート

遺伝子検査の世界市場:産業分析、市場見通し

Global Genetic Testing Market - Industry Analysis And Market Forecast 2015-2020

発行 Mordor Intelligence LLP 商品コード 319191
出版日 ページ情報 英文
納期: 即日から翌営業日
価格
本日の銀行送金レート: 1USD=105.42円で換算しております。
Back to Top
遺伝子検査の世界市場:産業分析、市場見通し Global Genetic Testing Market - Industry Analysis And Market Forecast 2015-2020
出版日: 2016年01月01日 ページ情報: 英文
概要

遺伝子検査は、病気のリスク予測、病気のキャリア特定、病気の診断、病気の経過予測などを目的に、遺伝子、染色体、タンパク質を分析することを言います。遺伝子検査には、細胞遺伝子検査、分子遺伝子検査、癌遺伝子検査、出生前スクリーニング、出生前診などがあります。遺伝子検査市場は、米国で2021年までに250億米ドル、世界で2020年までに約600億米ドル規模に達する見込みとなっております。

当レポートでは、世界の遺伝子検査市場について調査分析を行い、市場概要、市場因子、セグメンテーション別考察、地域別分析、競合状況、主要企業のプロファイルなどについてまとめています。

第1章 イントロダクション

  • レポートの説明
  • 調査方法

第2章 遺伝子検査市場の概要

  • 世界の遺伝子検査のイントロダクション

第3章 世界の遺伝子検査:市場因子

  • 市場促進因子
  • 市場抑制因子
  • 市場機会

第4章 世界の遺伝子検査市場:種類別

  • 概要
  • キャリア検査
  • 診断検査
  • 新生児スクリーニング
  • 予防的/発症前検査
  • 出生前検査

第5章 遺伝子検査市場:地域別

  • 概要
  • 北米
  • 欧州
  • アジア太平洋地域
  • 世界のその他の諸国

第6章 競合状況

第7章 企業プロファイル

  • ANDME, INC.
  • ABBOTT MOLECULAR
  • ARIOSA DIAGNOSTICS, Inc
  • BIOCARTIS SA
  • BIOHELIX CORPORATION (Quidelの完全所有子会社)
  • BIOMERIEUX S.A.
  • CELERA CORPORATION
  • CEPHEID
  • DAAN DIAGNOSTICS LTD.
  • EKF DIAGNOSTICS HOLDINGS PLC
  • GENENTECH, INC.
  • GENOMICTREE, INC.
  • HTG MOLECULAR DIAGNOSTICS, INC.
  • ILLUMINA, INC
  • INTEGRAGEN S.A
  • LABORATORY CORPORATION OF AMERICA HOLDINGS
  • LUMINEX CORPORATION
  • MOLECULARMD, CORP.
  • MYRIAD GENETICS, INC.
  • NATERA, INC.
  • OXFORD BIODYNAMICS LIMITED
  • PACIFIC BIOSCIENCES OF CALIFORNIA, INC.
  • PERKINELMER, INC.
  • QIAGEN N.V.
  • ROCHE DIAGNOSTICS LIMITED
  • SEEGENE, INC.
  • SEQUENOM, INC.
  • SIEMENS HEALTHCARE
  • TRANSGENOMIC, INC.

第8章 免責事項

このページに掲載されている内容は最新版と異なる場合があります。詳細はお問い合わせください。

目次

Global genetic testing market has been estimated to be valued at USD 37 billion in 2015 and is projected to reach USD 60 billion annually by 2020 with a compound annual growth rate (CAGR) of 10% during the forecast period 2015 to 2020.

Genetic testing is the analysis of chromosomes,DNA, RNA, genes or proteins to predict the risk of diseases, identify carriers of diseases and diagnose the disease or determine the likely course of a disease. Genetic testing is the most rapidly expanding segment of the worldwide molecular diagnostics market. The transformation of genetic testing from being a service-driven market to a product-driven market is expected to provide an impetus to the diagnostic companies for the expansion of their operations.

Genetic testing has become quite prevalent around the globe over the last few years with recent developments in molecular medicine and is expected to provide further impetus to this critical area. The European Commission, NIH and other organizations have recognized certain salient topics involving genetic testing that need further clarity, which include regional distribution of genetic services, suggestions for the rationalization of services, methods for improving national accreditation of genetic laboratories, long-term organization of external quality assessment, validation of next generation sequencing platforms and applications, perspectives on direct-to-consumer genetic testing.

The genetic testing market's growth is driven by increase in the genetic tests pipeline, early confirmation of genetic disorders, increasing incidence of diseases such as cancer, aging population and higher life expectancy. The technical advances, growing public awareness and demand for personalized medicine are the key factors that drive this market. The growing incidence of genetic diseases unravels new opportunities for genetic testing. However, high cost of genetic testing technologies remains as a key challenge for market growth.

The segmentation of the market for Genetic Testing is done based on Type (Carrier testing, diagnostic testing, new born screening, predictive and pre-symptomatic testing, and prenatal testing) .

Based on geographical location, the genetic testing market can be divided into North America (USA, Canada and Mexico), Europe (France, UK, Germany, Spain, Portugal, Scandinavia, Russia, and Italy), Asia-Pacific (India, China, Japan, South Korea, Australia, New Zealand), Middle East and Africa (GCC, Egypt) and Latin America (Brazil, Colombia and Argentina).

The major players in this market are Abbott Molecular, Biocartis SA., Celera Group, Cepheid, Genentech, Inc., IntegraGen S.A, Luminex Corporation, Qiagen N.V., Roche Diagnostics Limited, Transgenomic, Inc., among others.

Table of Contents

INTRODUCTION

  • Study deliveratives
  • Market Definition
  • Sizing Units
  • Base Currency
  • Review and forecasr period years
  • General Study Assumptions

RESEARCH METHODOLOGY

  • Introduction
  • Analysis Methodology
  • Econometric forecast models
  • Research Assumptions

EXECUTIVE SUMMARY

KEY INFERENCES

MARKET OVERVIEW AND INDUSTRY TRENDS

  • Current market scenario
  • Technology Overview
  • New developments in therapeutics
  • Investment analysis
  • Porters Five Force Analysis
  • Bargaining Power of suppliers
  • Bargaining power of buyers
  • Degree of competition
  • Threat of substitution
  • Threat of new entrants

DRIVERS, RESTRAINTS, OPPORTUNITIES AND CHALLENGES ANALYSIS (DROC)

  • Market Drivers
  • Increase in the genetic tests pipeline
  • Early confirmation of genetic disorders
  • Increasing incidence of diseases such as cancer
  • Aging population and higher life expectancy
  • Market Restraints
  • High cost of genetic testing technologies
  • Market Opportunities
  • Key Challenges
  • Global Genetic Testing Market Segmentation
  • By Type
  • Carrier testing
  • Diagnostic testing
  • New born screening
  • Predictive and pre-symptomatic testing
  • Prenatal testing
  • Global Genetic Testing market by Georaphy - Regional shares and forecast
  • North America
  • USA
  • Canada
  • Mexico
  • Europe
  • France
  • UK
  • Germany
  • Italy
  • Spain and Portugal
  • Scandinavia
  • BENELUX
  • Asia-Pacific
  • India
  • China
  • Japan
  • South Korea
  • Australia and New Zealand
  • Rest of Asia Pacific
  • Middle East and Africa
  • GCC
  • Egypt
  • Morocco
  • Algeria
  • South Africa
  • Rest of Middle East and Africa
  • Latin America
  • Brazil
  • Argentina
  • Rest of Latin America

COMPETITIVE LANDSCAPE

  • Mergers & Acquisitions
  • New Product Launches
  • Agreements, Collaborations & Partnerships

KEY VENDORS

  • Abbott Molecular
  • Biocartis SA
  • Celera Group
  • Cepheid
  • Genentech, Inc.
  • IntegraGen S.A
  • Luminex Corporation
  • Qiagen N.V.
  • Roche Diagnostics Limited
  • Transgenomic, Inc.
  • Analyst outlook for Investment Opportunities
  • Future outlook of the market

APPENDIX

  • Abbrevations
  • Bibliography
  • Disclaimer
Back to Top